Printer Friendly

CALIFORNIA BIOTECHNOLOGY NAMES DR. KENNETH LUSKEY TO DIRECTOR OF DIABETES AND OBESITY

 CALIFORNIA BIOTECHNOLOGY NAMES DR. KENNETH LUSKEY TO
 DIRECTOR OF DIABETES AND OBESITY
 MOUNTAIN VIEW, Calif., Dec. 3 /PRNewswire/ -- California Biotechnology Inc. (NASDAQ: CBIO) today announced that it has named Kenneth L. Luskey, M.D., as director of Diabetes and Obesity. Dr. Luskey joins Cal Bio following 10 years at the University of Texas Medical Center at Dallas where most recently he was associate professor, Center for Diabetes Research, Departments of Molecular Genetics and Internal Medicine.
 "The appointment of Dr. Luskey is part of a plan to expand and accelerate our efforts to discover new treatments for metabolic disorders, one of Cal Bio's key focus areas," commented John A. Lewicki, Cal Bio vice president and director of research. "The success of Cal Bio's program is highlighted by the discovery and ongoing development of two novel treatments for diabetes, insulinotropin and insulin analogs. We look forward to Dr. Luskey's contributions as he participates in the evaluation of new research projects, as well as plans and directs the research activities of our Diabetes and Obesity division."
 Insulinotropin, the first product to emerge from the metabolic disorders area, is currently undergoing Phase II testing as treatment for Type II diabetes. In addition, insulin analogs are in preclinical development for the treatment of Type I and Type II diabetes. Cal Bio's partner, Pfizer Inc., is carrying out the development of both products. In a move that underscores its confidence in the metabolic disorders program, Cal Bio recently announced that the company has acquired the outstanding minority interest in Metabolic Biosystems, Inc.
 Dr. Luskey, 40, received an M.D. from the University of Texas Southwestern Medical Center at Dallas in 1976 and a B.A. in 1972 from the University of Texas at Austin. He completed his internship and residency in medicine at Barnes Hospital, St. Louis, Mo. Dr. Luskey conducted his post doctoral studies in the University of Texas laboratories of Drs. Michael S. Brown and Joseph L. Goldstein, recipients of the 1985 Nobel Prize in Medicine.
 California Biotechnology Inc. is a biotechnology company engaged in the discovery, development, and commercialization of novel human therapeutics. Cal Bio focuses its efforts in three areas -- cardiopulmonary diseases, tissue repair, and metabolic disorders. The company develops and commercializes products on a proprietary basis and in collaboration with established pharmaceutical companies.
 -0- 12/3/91
 /CONTACT: Virginia Walker of Cal Bio, 415-940-6631 or 415-966-1550, or Robert Gottlieb of Feinstein Partners Inc., 617-577-8110/
 (CBIO) CO: California Biotechnology Inc. ST: California IN: MTC SU: PER


DG -- SJ003 -- 8740 12/03/91 12:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:423
Previous Article:HBO & COMPANY ISSUES STATEMENT
Next Article:CALIFORNIA BIOTECHNOLOGY NAMES DR. ELLIOTT GROSSBARD TO VICE PRESIDENT OF MEDICAL AND REGULATORY AFFAIRS
Topics:


Related Articles
CALIFORNIA BIOTECHNOLOGY NAMES DR. ELLIOTT GROSSBARD TO VICE PRESIDENT OF MEDICAL AND REGULATORY AFFAIRS
Amylin Pharmaceuticals Announces Management Promotions
Scientists at Hospital Saint-Vincent De Paul and GENSET Advance The Understanding of the Relationship Between Diabetes and Obesity.
World-Renowned Scientist Joins Scientific Advisory Board of CytRx Subsidiary.
CytRx Teams With World Renowned Scientists to Create Obesity and Type II Diabetes Program; - Company to Focus on Small Molecule Drugs Using RNAi...
Evotec OAI and DeveloGen Announce a Strategic Drug Discovery and Development Alliance for Metabolic Diseases.
Lexicon Genetics Appoints Philip M. Brown, M.D., J.D. Vice President Of Clinical Development.
Nara Biosciences Inc. Inks License Agreement for MyoMouse Platform.
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters